Veklury (Remdesivir) Drug Vials Recalled for Glass Particulate Matter
Gilead Sciences is recalling Veklury (remdesivir) injection vials nationwide due to the presence of glass particulates detected during a customer complaint investigation. The affected lots are 2141001-1A and 2141002-1A with expiration date 01/2024.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I recall as stated in the source metadata. The presence of glass particulates in an intravenous injection product presents a risk of serious injury, meeting the Class I threshold for a drug recall.
Plain-English summary
Gilead Sciences, Inc. is recalling Veklury (remdesivir) for injection, 100 mg/vial, a prescription antiviral medication. The recall affects 53,473 single-dose vials distributed nationwide in the United States. The recall was initiated after investigation into a customer complaint confirmed the presence of glass particulates in the product.
The affected lots are 2141001-1A and 2141002-1A, with expiration date 01/2024. The product is manufactured by Gilead Sciences, Inc., Foster City, CA 94404, with NDC 61958-2901-2.
Healthcare providers and patients who have received or are in possession of affected vials should discontinue use immediately. Patients should contact their healthcare provider for guidance on alternative treatment options.
The recalled product
- Product
- VEKLURY (REMDESIVIR)
- Brand
- VEKLURY
- Manufacturer
- Gilead Sciences, Inc.
- Category
- Drug — Injectable / Antiviral
- Hazard
- glass-contamination
- particulate-matter
- injection-hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: 2141001-1A
- 2141002-1A
- Exp. 01/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · VEKLURY
- SevereFDA Recalls Veklury Injection Vials for Presence of Glass Particles
FDA (Drugs) · 2024-10-09
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27